Pandemic influenza vaccine distribution selected updates
Download
1 / 14

Pandemic Influenza Vaccine Distribution Selected Updates - PowerPoint PPT Presentation


  • 132 Views
  • Uploaded on

Pandemic Influenza Vaccine Distribution Selected Updates. Pandemic Influenza Vaccine: Doses Administered and Safety Training Conference Toscha Stanley, MHSA Immunization Services Division Centers for Disease Control and Prevention (CDC) August 21, 2008. Vaccination periods.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Pandemic Influenza Vaccine Distribution Selected Updates' - cedric-greene


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Pandemic influenza vaccine distribution selected updates

Pandemic Influenza Vaccine Distribution Selected Updates

Pandemic Influenza Vaccine:

Doses Administered and Safety Training Conference

Toscha Stanley, MHSA

Immunization Services Division

Centers for Disease Control and Prevention (CDC)

August 21, 2008


Vaccination periods
Vaccination periods

  • Five vaccination periods (take into account both timing and supply)

    • Preparation period

    • Pre-pandemic influenza vaccination period

    • Manufacturing period

    • Early pandemic influenza vaccination period

    • Later pandemic influenza vaccination period


Vaccine distribution
Vaccine distribution

  • Initial demand expected to exceed supply

    • When (demand >>> supply): allocation “push” model

    • When (demand > supply): may transition to “pull” model

  • Vaccine distribution will be monitored via CDC’s FluFinder

  • States will be able to access FluFinder data for their individual state through the CDC secure data network


Direct distribution
Direct distribution

  • Manufacturer ships vaccine to states using its established distribution channels (commercial shipper or 3rd party distributor)

  • May involve single or multiple manufacturers depending on the current state of domestic manufacturing capacity


Ship-to site 1

(50%)

Ship-to site 1

(60%)

POD

POD

POD

POD

POD

POD

Ship-to site 2

(25%)

Ship-to site 2

(30%)

POD

POD

POD

POD

POD

POD

Ship-to site 3

(10%)

Ship-to site 3

(25%)

POD

POD

POD

POD

POD

POD

State B (2% of U.S. supply)

State A (4% of U.S. supply)

Vaccine manufacturer A

Needle/syringe manufacturer

CDC and HHS

Vaccine manufacturer B

3rd party distributor

Direct distribution: Pre-pandemic influenza vaccine distribution with multiple manufacturers jointly supplying states


Ship-to site 1

(50%)

Ship-to site 1

(60%)

POD

POD

POD

POD

POD

POD

Ship-to site 2

(30%)

Ship-to site 2

(25%)

POD

POD

POD

POD

POD

POD

Ship-to site 3

(10%)

Ship-to site 3

(25%)

POD

POD

POD

POD

POD

POD

State A (4% of U.S. supply)

State B (2% of U.S. supply)

CDC and HHS

Needle/syringe manufacturer

Vaccine manufacturer A

Direct distribution: Pandemic influenza vaccine distribution with a single manufacturer


Operations at the state level
Operations at the state level

  • State-designated ship-to sites must be capable of:

    • Receiving

    • Storing

    • Securing

    • Repackaging

    • Allocating to PODs

    • Follow-on distribution to PODs

  • Allocation, distribution, and administration within a state will be a state and local function


Ship to sites
Ship-to sites

  • Total # of Pre-pandemic vax ship-to sites = 623

  • Total # of Pandemic vax ship-to sites = 976

    1 site2-10 sites>10 sites

    Pre-Pandemic 43 9 10

    Pandemic 38 8 16

  • Federal ship-to sites


POD 1

POD 2

Single central

ship-to site

Vaccine, adjuvant, needles and syringes

POD 3

POD 4

POD 5

State X: Single central ship-to site with direct shipment to PODs


POD 1

Regional

sub-ship-to site #1

POD 2

Vaccine manufacturer or distributor

Single Central

ship-to site

POD 3

POD 4

Regional

Sub-ship-to site #2

POD 5

State Z: Single ship-to site with regional sub-ship-to sites within the state


POD 1

Ship-to site

#1

POD 2

Ship-to site

#2

Vaccine, adjuvant, needles and syringes

POD 3

POD 4

Ship-to site

#3

POD 5

State Y: Multiple ship-to sites with direct shipment to PODs


The findings and conclusions in this presentation have not been formally disseminated by CDC and should not be construed to represent any agency determination or policy.


Extra slides
Extra Slides been formally disseminated by CDC and should not be construed to represent any agency determination or policy.


Ship-to site 1 been formally disseminated by CDC and should not be construed to represent any agency determination or policy.

(50%)

Ship-to site 1

(60%)

POD

POD

POD

POD

POD

POD

Ship-to site 2

(25%)

Ship-to site 2

(30%)

POD

POD

POD

POD

POD

POD

Ship-to site 3

(10%)

Ship-to site 3

(25%)

POD

POD

POD

POD

POD

POD

State A (4% of U.S. supply)

State B (2% of U.S. supply)

Centralized Distribution Option

Vaccine manufacturer A

CDC and HHS

Central distributor

Needle/syringe manufacturer

Vaccine manufacturer B

Centralized distribution: Multiple manufacturers and multiple products


ad